1. Cytoskeleton
  2. Integrin
  3. Abciximab

Abciximab  (Synonyms: C7E3)

Cat. No.: HY-P9934 Purity: 99.966%
COA

Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.

For research use only. We do not sell to patients.

Abciximab Chemical Structure

Abciximab Chemical Structure

CAS No. : 143653-53-6

Size Price Stock Quantity
1 mg USD 260 In-stock
5 mg USD 680 In-stock
10 mg USD 1090 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

View All Integrin Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors[1].

In Vitro

Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet αIIbβ3 integrin[2].
Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats weighing 200-250 g, balloon angioplasty model[2]
Dosage: 0.25 mg/kg/day
Administration: Intravenous injection, 28 days
Result: Time-dependently inhibited both neointimal hyperplasia and lumen occlusion after angioplasty in carotid arteries of rats. Significantly reduced PDGF-BB expression in vessel lumens and neointimal smooth muscle cells after angioplasty. Suppressed the elevation of plasma TxB2 concentration.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Abciximab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 99.966%

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Abciximab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Abciximab
Cat. No.:
HY-P9934
Quantity:
MCE Japan Authorized Agent: